Testing at the bedside . . . and other storiesBMJ 2017; 357 doi: https://doi.org/10.1136/bmj.j1942 (Published 27 April 2017) Cite this as: BMJ 2017;357:j1942
Point of care virus testing
A test that identifies respiratory viruses by the bedside should be a godsend for cutting the use of antibacterial drugs. But when tried over two winters in a large British hospital, it wasn’t (Lancet Respir Med doi:10.1016/S2213-2600(17)30120-0). The ResPOC trial enrolled adults within 24 hours of presenting to the emergency department or acute medical unit with acute respiratory illness or fever higher than 37.5°C (≤7 days duration), or both, and randomised them to have a molecular point of care test for respiratory viruses or routine clinical care. Those in the intervention group who tested positive for influenza virus were more likely to receive an antiviral, but overall antibiotic use did not vary between the groups.
Morbidity after open aortic valve surgery
Aortic stenosis is common and likely …